Kamol

[Kamol @KamolMU]

https://t.co/Z1rgUBGIyi

[โดน้าท ^›⩊‹^ ੭ @chrysolaminarie]

วันนี้จะมาเล่าเรื่อง🦎💉 ปากกาลดน้ำหนัก (GLP-1 receptor agonists): เรื่องเล่าจากน้ำลายกิ้งก่าสู่ยาที่เปลี่ยนโลก — a thread

[Kamol @KamolMU]

Happy 3rd Anniversary to Whiteout Survival!
Three years of surviving the frost, building cities, and fighting together with allies around the world.
Here’s to many more years of adventure in the frozen wasteland! ❄️⚔️

#whiteoutsurvival #wos3ndanniversary
ID: 656510190

[Jacopo Imberti @JacopoImberti]

📣Pillars of #Afib management

🧐
A- Easy as ABC
B- an SOS
C- handle with CARE

➡️Remember integrated holistic care!

#ESCCongress #Guidelines @LiverpoolCCS @Dominik_Linz @ESC_Journals @Phiso_de @DavidDuncker

[SMMCE @SMMCE_MX]

🩸 Ácido tranexámico: Revisión ilustrativa.

Completa y menciona los artículos más relevantes respecto a la evidencia de su uso.

Gratis

https://t.co/erLKMepTz3

[The Heart @ZHeart11768530]

🔴 DOACs should not be the standard treatment for patients with mechanical heart valves, #AFib , rheumatic mitral stenosis or antiphospholipid syndrome

📍Read key points from a #JACC state-of-the-art review on when DOACs should not be standard treatment https://t.co/IfLL9pqObz

[AHA Science @AHAScience]

1/ Published today: The updated evidence-based recommendations for managing Lower Extremity PAD, originally outlined in the 2016 Guideline, now incorporate the latest research findings to assist clinicians.

✍🏽:@heatherlgornik

📖: @CircAHA

[The Heart @ZHeart11768530]

🔴 Diagnosis and treatment of deep vein thrombosis of the lower and upper limbs. 2024 recommendations

https://t.co/U2a1Ct1MsW
#MedTwitter #CardioTwitter #ACC2024
#CardioEd #Cardiology #FOAMed #meded #MedEd #Cardiology #CardioTwitter #cardiotwitter #cardiotwiteros #CardioEd

[Gunnar Henrik Heine @gunnar_heine]

Highly convincing data from @brendonneuen and SMART-C that use of GLP-1 RA neither affects the efficacy, nor the safety, of SGLT-2 I.
https://t.co/gwGtaCLgKR
After FLOW comes the question whether SGLT-2 I affects the efficacy of GLP-1 RA.

[ERA - European Renal Association @ERAkidney]

1/ Richard Pratley @RpratleyMD talking about design #ERA24
🔸 randomized, double-blind, parallel-group, multinational, phase 3b trial
🔸randomized 1:1 to once weekly semaglutide 1.0 mg or matched placebo,
💉once weekly subcutaneous semaglutide versus placebo
🔸 event-driven trial
🔸Included countries from all the continents

[The Heart @ZHeart11768530]

🔴 Aspirin hypersensitivity: a practical guide for cardiologists : State of the Art Review
@ESC_Journals

https://t.co/jPKUDV49QI
#acute #coronary #syndrome #aspirin #hypersensitivity #MedX #MedTwitter #CardioTwitter #medx #medEd #MedTwitter #MedEd #cardiotwitter #FOAMed

[Kamol @KamolMU]

RT @goKDIGO: KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Evaluation and Management of Chro…

[The Heart @ZHeart11768530]

🔴 Use of Intravenous Albumin: A #2024 Guideline from the International Collaboration for Transfusion Medicine Guidelines #openaccess

https://t.co/8gW1RhBX4s
#medical #cardiology #cardiotwitter #meded #CardioEd #cardiox #medicine #medtwitter

[KDIGO @goKDIGO]

We are pleased to announce the publication of the KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis, published today in the March issue of Supplement to Kidney International, with an Executive Summary in the main pages of the journal.

Read the news release: https://t.co/ewZokps7wF

Read the guideline in Kidney International: https://t.co/M9Y1QBeS6s

Visit the KDIGO ANCA Vasculitis Website: https://t.co/oBR5IPukpe

Developed under the stewardship of Co-Chairs Brad Rovin, MD (US) and Jürgen Floege, MD (DE), this guideline is an update to the ANCA Vasculitis chapter of the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

"The ANCA Vasculitis Guideline includes significant updates aimed at enhancing clinical decision-making, integrating new treatments with established clinical practices," stated Dr. Floege. "We anticipate that the comprehensive research, clinical perspectives, and collaborative expertise reflected in this guideline will contribute to better outcomes for individuals grappling with this complex condition."

"We are excited to release the KDIGO 2024 ANCA Vasculitis Guideline, which offers new guidance for managing the intricacies of ANCA vasculitis treatment, particularly with the emergence of innovative therapies," said Dr. Rovin. "We are better equipped than ever to tailor interventions, optimize patient care, and strive towards improved outcomes for people with ANCA-associated vasculitis."

KDIGO thanks the Guideline Work Group for their dedication and expertise and the Evidence Review Team from Brown University School of Public Health for their comprehensive work on this guideline.

#ANCA #vasculitis #AAV #glomerular

[Lohith_Rebel @Rebelism_18]

@PicturesFoIder Perfect loop exists

[AHA Science @AHAScience]

SELECT results presented at #AHA23

[GoggleDocs @GoggleDocs]

‼️SELECT trial - Semaglutide 2.4mg in those with obesity/overweight 🚫diabetes‼️#AHA2023

🔹Inclusion: >45yrs, BMI >27, eASCVD (stroke/MI/symptomatic PAD)
🔸mean age 61.6, BMI 33.3, 72% male
🔹PEP : 3P MACE - achieved!
HR 0.80, p<0.001
🔸Just missed CV mortality p0.07… interesting trend 🤔 so 2ndry outcomes - pinch of 🧂
🔹Numerical reduction hHF (expected but interesting to see details)
🔸Numerical reduction all cause mortality (again- details will be interesting!)
🔹Nonetheless - first CVOT incretin trial in those without diabetes shows benefit! Implications for clinical care!

Stay tuned for more from us!

https://t.co/6NfcafUeYS

@kamleshkhunti @DLBHATTMD @AmarPut @drpatrickholmes @dr_amritlamba @mmamas1973 @DrRaniKhatib @redGDPS @kaulcsmc @BevTchangMD

[C. Michael Gibson MD @CMichaelGibson]

BREAKING

Mike Lincoff presents results of SELECT: In pts with CVD &amp; BMI &gt; 27 CV death, MI and stroke reduced by 20% from 8 to 6.5% over 3 years

[Henry Han @HanCardiomd]

In a study with 17,604 patients, #semaglutide showed a significant reduction in major CV events compared to placebo (6.5% vs 8.0%, HR 0.80, P<0.001) over ~40 months.

There were no unexpected safety findings, although well-known GI side effects drove a higher rate of permanent treatment discontinuation in the semaglutide arm (16.6% vs 8.2%; P < 0.001)

https://t.co/rvFIiBJusY @NEJM #AHA23

[无羁😎 @heijix86]

Handouts A-Z in cardiology 💓
https://t.co/Nnyr0wMLPj

[SABOURETCardiologist @SABOURETCardio]

2023 ESC Guidelines on ACS: what is new in antithrombotic therapy? | European Heart Journal - Cardiovascular Pharmacotherapy #EHJCVP #SAPT #DAPT #PreTx https://t.co/6LKO6BH1lZ